🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10167334

Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

The Regents of the University of California · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10160802

Anti-malarial compositions

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10155798

Anti-obesity compounds derived from neuromedin U

The Regents of the University of California · Granted Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10144767

Anti-microbial peptides and coatings

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10143724

Anti-SSX-2 T cell receptors and related materials and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10137104

Combination therapy with an anti-hyaluronan agent and therapeutic agent

HALOZYME, INC. · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10138298

Anti-IL-2 antibodies and compositions and uses thereof

The Regents of the University of California · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10123974

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10118938

Arsenoplatin anti-cancer agents

Northwestern University · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10117882

Anti-inflammatory properties of marine lipid compositions

AKER BIOMARINE ANTARCTIC AS · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10106620

Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10100012

Compounds as anti-tubercular agents

DRUG DISCOVERY RESEARCH CENTRE · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10093745

Anti-CSPG4 fusions with interferon for the treatment of malignancy

The Regents of the University of California · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10087230

Murine anti-NY-ESO-1 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10080739

Aryl imidazoles and their use as anti-cancer agents

APTOSE BIOSCIENCES INC. · Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072086

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072070

Potent anti-influenza A neuraminidase subtype N1 antibody

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072051

Anti-inflammatory lipopeptide and preparing method and application thereof

EAST CHINA NORMAL UNIVERSITY · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10059762

Anti-EGFR activatable antibodies

CytomX Therapeutics, Inc. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10047160

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10040858

Anti-CSF1R antibodies for treating PVNS

Five Prime Therapeutics, Inc. · Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10028911

Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (D

Pacira Pharmaceuticals, Inc. · Granted Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023641

Anti-TIE2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023916

Markers of tumor cell response to anti-cancer therapy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted